Lincoln Pharmaceuticals posts Q1 FY24 standalone net profit at Rs. 19.01 Cr

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

Syngene to acquire multi-modal facility from Stelis Biopharma

Adding 20,000 liters of installed biologics drug substance manufacturing capacity

Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth

JB Pharma completes 1 year of its identity launch

Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

Aurobindo Pharma Q4 FY23 PAT up at Rs. 506 Cr

US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore